Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person UniProt:P27986 PIK3R1
| Class:Id | ReferenceGeneProduct:61192 |
|---|---|
| _chainChangeLog | initiator methionine:1 added on Fri February 6 2015;chain:2-724 added on Fri February 6 2015;initiator methionine:1 for 61192 removed on Fri Nov 03 2023;initiator methionine: for 61192 added on Fri Nov 03 2023;initiator methionine: for 61192 removed on Fri Aug 15 2025;initiator methionine:1 for 61192 added on Fri Aug 15 2025 |
| _displayName | UniProt:P27986 PIK3R1 |
| _timestamp | 2025-08-15 21:47:29 |
| chain | initiator methionine:1 chain:2-724 |
| checksum | B9DAD8416C33140F |
| comment | FUNCTION Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling (PubMed:17626883, PubMed:19805105, PubMed:7518429). Modulates the cellular response to ER stress by promoting nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement (PubMed:20348923).SUBUNIT Heterodimer of a regulatory subunit PIK3R1 and a p110 catalytic subunit (PIK3CA, PIK3CB or PIK3CD). Interacts (via SH2 domains) with CCDC88A/GIV (tyrosine-phosphorylated form); the interaction enables recruitment of PIK3R1 to the EGFR receptor, enhancing PI3K activity and cell migration (PubMed:21954290). Interacts (via SH2 domain) with CSF1R (tyrosine phosphorylated). Interacts with PIK3R2; the interaction is dissociated in an insulin-dependent manner (By similarity). Interacts with XBP1 isoform 2; the interaction is direct and induces translocation of XBP1 isoform 2 into the nucleus in a ER stress- and/or insulin-dependent but PI3K-independent manner (PubMed:20348923). Interacts with FER. Interacts (via SH2 domain) with TEK/TIE2 (tyrosine phosphorylated). Interacts with PTK2/FAK1 (By similarity). Interacts with phosphorylated TOM1L1. Interacts with phosphorylated LIME1 upon TCR and/or BCR activation. Interacts with SOCS7. Interacts with RUFY3. Interacts (via SH2 domain) with CSF1R (tyrosine phosphorylated). Interacts with LYN (via SH3 domain); this enhances enzyme activity (By similarity). Interacts with phosphorylated LAT, LAX1 and TRAT1 upon TCR activation. Interacts with CBLB. The SH2 domains interact with the YTHM motif of phosphorylated INSR in vitro. Also interacts with tyrosine-phosphorylated IGF1R in vitro. Interacts with CD28 and CD3Z upon T-cell activation. Interacts with IRS1, IRS2 and phosphorylated IRS4, as well as with NISCH and HCST (PubMed:8628286, PubMed:19109239). Interacts with FASLG, KIT and BCR. Interacts with AXL, FGFR1, FGFR2, FGFR3 and FGFR4 (phosphorylated). Interacts with FGR and HCK. Interacts with PDGFRA (tyrosine phosphorylated) and PDGFRB (tyrosine phosphorylated). Interacts with ERBB4 (phosphorylated). Interacts with NTRK1 (phosphorylated upon ligand-binding). Interacts with FAM83B; activates the PI3K/AKT signaling cascade (PubMed:23676467). Interacts with APPL1 and APPL2 (By similarity). Interacts with SRC (PubMed:28903391). Interacts with ALOX5; this interaction bridges ALOX5 with CD40 after CD40 ligation in B cells and leads to the production of reactive oxygen species (ROS) (PubMed:21200133). Interacts with TYK2 (PubMed:10995743). Interacts with nephrin NPHN1; the interaction is reduced by high glucose levels (PubMed:28955049). Interacts with CASP8 (phosphorylated on Tyr-380) (PubMed:27109099). Interacts with CD28 (PubMed:7568038). Interacts with ICOS (PubMed:30523347).SUBUNIT (Microbial infection) Interacts with HIV-1 Nef to activate the Nef associated p21-activated kinase (PAK). This interaction depends on the C-terminus of both proteins and leads to increased production of HIV.SUBUNIT (Microbial infection) Interacts with HCV NS5A.SUBUNIT (Microbial infection) Interacts with herpes simplex virus 1 UL46; this interaction activates the PI3K/AKT pathway.SUBUNIT (Microbial infection) Interacts with herpes simplex virus 1 UL46 and varicella virus ORF12; this interaction activates the PI3K/AKT pathway.INTERACTION Isoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level).DOMAIN The SH3 domain mediates the binding to CBLB, and to HIV-1 Nef.PTM Polyubiquitinated in T-cells by CBLB; which does not promote proteasomal degradation but impairs association with CD28 and CD3Z upon T-cell activation.PTM In adipose tissue, polyubiquitinated by the BCR(KBTBD2) E3 ubiquitin ligase complex; recognized by KBTBD2 through the SH2 domains, undergoes 'Lys-48'-linked polyubiquitination leading to its degradation.PTM Phosphorylated. Tyrosine phosphorylated in response to signaling by FGFR1, FGFR2, FGFR3 and FGFR4. Phosphorylated by CSF1R. Phosphorylated by ERBB4. Phosphorylated on tyrosine residues by TEK/TIE2. Dephosphorylated by PTPRJ. Phosphorylated by PIK3CA at Ser-608; phosphorylation is stimulated by insulin and PDGF. The relevance of phosphorylation by PIK3CA is however unclear (By similarity). Phosphorylated in response to KIT and KITLG/SCF. Phosphorylated by FGR.DISEASE The disease is caused by variants affecting the gene represented in this entry.DISEASE The disease is caused by variants affecting the gene represented in this entry.DISEASE The disease is caused by variants affecting the gene represented in this entry.SIMILARITY Belongs to the PI3K p85 subunit family. |
| description | recommendedName: Phosphatidylinositol 3-kinase regulatory subunit alpha shortName: PI3-kinase regulatory subunit alpha shortName: PI3K regulatory subunit alpha shortName: PtdIns-3-kinase regulatory subunit alpha alternativeName: Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha shortName: PI3-kinase subunit p85-alpha shortName: PtdIns-3-kinase regulatory subunit p85-alpha |
| geneName | PIK3R1 GRB1 |
| identifier | P27986 |
| isSequenceChanged | FALSE |
| keyword | 3D-structure Acetylation Alternative splicing Disease variant Dwarfism GTPase activation Host-virus interaction Phosphoprotein Protein transport Proteomics identification Reference proteome Repeat SH2 domain SH3 domain Stress response Transport Ubl conjugation |
| modified | [InstanceEdit:9836292] Weiser, Joel, 2023-05-25 [InstanceEdit:9852000] Weiser, Joel, 2023-11-03 [InstanceEdit:9909836] Weiser, Joel, 2024-05-14 [InstanceEdit:9917590] Weiser, Joel, 2024-08-09 [InstanceEdit:9926675] Weiser, Joel, 2024-11-03 [InstanceEdit:9939033] Weiser, Joel, 2025-02-21 [InstanceEdit:9963647] Weiser, Joel, 2025-08-15 |
| name | PIK3R1 |
| referenceDatabase | [ReferenceDatabase:2] UniProt |
| referenceGene | [ReferenceDNASequence:8948431] ENSEMBL:ENSG00000145675 PIK3R1 [Homo sapiens] |
| secondaryIdentifier | P85A_HUMAN B3KT19 D3DWA0 E7EX19 Q15747 Q4VBZ7 Q53EM6 Q8IXA2 Q8N1C5 |
| sequenceLength | 724 |
| species | [Species:48887] Homo sapiens |
| (isoformParent) | [ReferenceIsoform:241488] UniProt:P27986-2 PIK3R1 [Homo sapiens] [ReferenceIsoform:241489] UniProt:P27986-3 PIK3R1 [Homo sapiens] [ReferenceIsoform:241490] UniProt:P27986-4 PIK3R1 [Homo sapiens] [ReferenceIsoform:403512] UniProt:P27986-1 PIK3R1 [Homo sapiens] [ReferenceIsoform:8975683] UniProt:P27986-5 PIK3R1 [Homo sapiens] |
| (referenceEntity) | [EntityWithAccessionedSequence:74789] PIK3R1 [cytosol] [Homo sapiens] [EntityWithAccessionedSequence:198365] PIK3R1 [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:2399421] PIK3R1 D560Y [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:2399427] PIK3R1 N564D [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:2399431] PIK3R1 N564K [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:2399432] PIK3R1 D560H [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:2399536] PIK3R1 R574I [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:2399540] PIK3R1 R574T [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:2399544] PIK3R1 R574_T576del [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:2399545] PIK3R1 H450_E451del [plasma membrane] [Homo sapiens] |
| (referenceSequence) | [ReplacedResidue:2399424] L-asparagine 564 replaced with L-aspartic acid [ReplacedResidue:2399425] L-asparagine 564 replaced with L-lysine [ReplacedResidue:2399426] L-aspartic acid 560 replaced with L-histidine [ReplacedResidue:2399429] L-aspartic acid 560 replaced with L-tyrosine [ReplacedResidue:2399535] L-arginine 574 replaced with L-isoleucine [ReplacedResidue:2399538] L-arginine 574 replaced with L-threonine [FragmentDeletionModification:2399543] Deletion of residues 463 to 466 [FragmentDeletionModification:2399547] Deletion of residues 450 to 451 [FragmentDeletionModification:2399548] Deletion of residues 459 to 459 [FragmentDeletionModification:2399552] Deletion of residues 574 to 576 |
| [Change default viewing format] | |
No pathways have been reviewed or authored by UniProt:P27986 PIK3R1 (61192)
